Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Irhythm Technologies Inc (NQ: IRTC )

74.36 -1.23 (-1.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 757,822
Open 76.17
Bid (Size) 73.50 (4)
Ask (Size) 76.00 (3)
Prev. Close 75.59
Today's Range 72.47 - 76.41
52wk Range 55.92 - 124.11
Shares Outstanding 29,403,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
Via Benzinga
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
FDA approves iRhythm's 510(k) submission for Zio AT device. A second approval may come soon, enhancing the company's mobile cardiac telemetry services. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-26.62%
-26.62%
1 Month
+6.15%
+6.15%
3 Month
-23.62%
-23.62%
6 Month
-36.13%
-36.13%
1 Year
-7.37%
-7.37%

More News

Read More
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss iRhythm Technologies Stock
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
From iRhythm
Via GlobeNewswire
Key Takeaways From iRhythm Technologies Analyst Ratings
Via Benzinga
Expert Ratings For iRhythm Technologies
Via Benzinga
4 Analysts Assess iRhythm Technologies: What You Need To Know
Via Benzinga
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
From iRhythm
Via GlobeNewswire
iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
From iRhythm
Via GlobeNewswire
iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Results of GUARD-AF Trial
From iRhythm
Via GlobeNewswire
Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday
Via Benzinga
iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Participate in Upcoming Investor Conferences in September
From iRhythm
Via GlobeNewswire
IRTC Stock Earnings: iRhythm Technologies Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
iRhythm Technologies Announces Chief Financial Officer Transition
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Second Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
7 Leading MedTech Stocks for Next-Gen Health Solutions
Via InvestorPlace
7 Robotics Stocks That Could Grow Your Wealth
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.